ELDN Stock Overview
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Eledon Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.97 |
| 52 Week High | US$2.95 |
| 52 Week Low | US$1.07 |
| Beta | 0.93 |
| 1 Month Change | -4.83% |
| 3 Month Change | 8.84% |
| 1 Year Change | -12.05% |
| 3 Year Change | -80.86% |
| 5 Year Change | -96.06% |
| Change since IPO | -98.28% |
Recent News & Updates
We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully
Mar 22
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?
Dec 05Recent updates
We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully
Mar 22Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?
Dec 05Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?
Aug 10We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully
Apr 27Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation
Jan 05Eledon adds 10% as FDA clears clinical trial for kidney disease candidate
Sep 06Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?
Aug 31Eledon gets FDA nod to start trial of organ rejection preventing therapy
Aug 01Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patients
Jul 18Eledon gives update on development strategy for AT-1501 in renal transplantation
Apr 26Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans
Apr 14What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?
Feb 21Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation
Dec 30
Novus Therapeutics (NVUS) Investor Presentation - Slideshow
Dec 18Novus Therapeutics EPS misses by $3.76
Nov 16Enrollment underway in Novus Therapeutics' mid-stage AT-1501 trial in neuromuscular disease
Nov 02Shareholder Returns
| ELDN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 25.5% | 1.0% | 1.2% |
| 1Y | -12.1% | 0.7% | 24.9% |
Price Volatility
| ELDN volatility | |
|---|---|
| ELDN Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Volatility Over Time: ELDN's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 20 | DA Gros | eledon.com |
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential.
Eledon Pharmaceuticals, Inc. Fundamentals Summary
| ELDN fundamental statistics | |
|---|---|
| Market cap | US$53.60m |
| Earnings (TTM) | -US$40.33m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs ELDN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ELDN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$40.33m |
| Earnings | -US$40.33m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.63 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ELDN perform over the long term?
See historical performance and comparison